3 New HCV Treatment Article Summaries and Links

[Guest guest]

HIVandHepatitis.com

FDA Hearings Next Week on Boceprevir and Telaprevir for HCV

SUMMARY

FDA Antiviral Drugs Advisory Committee will hear evidence for boceprevir on

April 27 and telaprevir on April 28.

Tegobuvir Works Well in Triple and Quad Regimens for HCV

SUMMARY

Gilead's HCV polymerase inhibitor tegobuvir (GS-9190) improved response rates in

treatment-naive genotype 1 patients when used in various combinations with

pegylated interferon, ribavirin, and the experimental protease inhibitor

GS-9256, researchers reported at EASL 2011

HIV/HCV Coinfection among HIV Positive Gay Men

SUMMARY

Researchers at EASL presented further data on outbreaks of sexually transmitted

HCV among HIV positive men who have sex with men. Sustained response rates are

high when interferon-based therapy is started during acute infection, but

re-infection after treatment is common in this population.